Science-Based Evaluation Advocates Want Tighter Homeopathic Oversight
This article was originally published in The Tan Sheet
Executive Summary
Public health concerns should prompt FDA to tighten its regulation of homeopathic drugs, a citizen petition filed by the nonprofit Center for Inquiry says.
You may also be interested in...
FTC Homeopathic Disclaimer Policy Should Prompt FDA Changes – Advocacy Group
Center for Inquiry reiterates its criticism of homeopathy and calls on FDA to step up vetting of US-marketed homeopathic products.
FTC Homeopathic Disclaimer Policy Should Prompt FDA Changes – Advocacy Group
Center for Inquiry reiterates its criticism of homeopathy and calls on FDA to step up vetting of US-marketed homeopathic products.
Homeopathic Regulation Critics Will Swing For Change Against Industry Stalwarts At FDA Hearing
In addition to marketers and trade groups, Gary Yingling, a former FDA counsel involved in the agency’s decision to omit homeopathics from the OTC drug review, will make a presentation at a public hearing April 20-21. FDA’s current approach as “a rational framework,” CHPA says.